目的:探讨多囊卵巢综合征(PCOS)患者不同时期血浆Nesfatin-1水平的变化。方法:选择健康育龄妇女33例和PCOS不孕患者30例,于经期2~3天时期采集前臂静脉血,ELISA方法测定血浆Nesfatin-1,常规方法测定性激素进行比较;另选择20例PCOS患者口服避孕药达英35加二甲双胍调节月经周期两周期,与用药前进行自身血浆Nesfatin-1水平比较,观察有无变化。结果:PCOS患者血浆Nesfatin-1水平低于健康妇女,血LH、T水平高于健康妇女,差异有统计学意义(P<0.05),余性激素差异无统计学意义(P>0.05);PCOS患者用药后血浆Nesfatin-1水平高于用药前,差异有统计学意义(P<0.05)。结论:多囊卵巢综合征患者血浆Nesfatin-1低于健康妇女,口服达英-35加二甲双胍两周期后患者血浆Nesfatin-1水平上升。 Objective: To investigate the plasma levels of Nesfatin-1 in patients with polycystic ovary syndrome (PCOS) at different periods. Methods: Thirty-three healthy women of childbearing age and 30 infertile women with PCOS were enrolled in this study. Forearm venous blood was collected during 2 to 3 days of menstruation, serum Nesfatin-1 was assayed by ELISA, and sex hormones were determined by routine method. Contraceptives up to British 35 plus metformin regulation of menstrual cycle two cycles, and medication before the level of plasma Nesfatin-1 compared to observe whether the change. Results: The plasma level of Nesfatin-1 in patients with PCOS was lower than that in healthy women, and the levels of serum LH and T were higher than those in healthy women (P <0.05). There was no significant difference in excess hormones between PCOS patients and PCOS patients Plasma Nesfatin-1 level after treatment was higher than before treatment, the difference was statistically significant (P <0.05). CONCLUSIONS: Plasma Nesfatin-1 levels in patients with polycystic ovary syndrome are lower than those in healthy women, and plasma Nesfatin-1 levels are elevated in patients receiving oral up to -35 plus metformin for two cycles.